KR970703165A - 미코박테리아성 감염에 대한 백신(vaccine against mycobacterial infections) - Google Patents
미코박테리아성 감염에 대한 백신(vaccine against mycobacterial infections) Download PDFInfo
- Publication number
- KR970703165A KR970703165A KR1019960706527A KR19960706527A KR970703165A KR 970703165 A KR970703165 A KR 970703165A KR 1019960706527 A KR1019960706527 A KR 1019960706527A KR 19960706527 A KR19960706527 A KR 19960706527A KR 970703165 A KR970703165 A KR 970703165A
- Authority
- KR
- South Korea
- Prior art keywords
- nucleic acid
- acid construct
- naked nucleic
- coding sequence
- antigen
- Prior art date
Links
- 206010062207 Mycobacterial infection Diseases 0.000 title claims abstract 6
- 208000027531 mycobacterial infectious disease Diseases 0.000 title claims abstract 6
- 229960005486 vaccine Drugs 0.000 title claims abstract 6
- 208000015181 infectious disease Diseases 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 19
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 18
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 18
- 101710201541 Proline-rich antigen Proteins 0.000 claims abstract description 8
- 108091026890 Coding region Proteins 0.000 claims abstract 11
- 239000000427 antigen Substances 0.000 claims abstract 5
- 102000036639 antigens Human genes 0.000 claims abstract 5
- 108091007433 antigens Proteins 0.000 claims abstract 5
- 239000012634 fragment Substances 0.000 claims abstract 5
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims abstract 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims abstract 4
- 210000002798 bone marrow cell Anatomy 0.000 claims description 9
- 239000013612 plasmid Substances 0.000 claims description 9
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 3
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 101710122462 65 kDa protein Proteins 0.000 claims 1
- 101710104159 Chaperonin GroEL Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 claims 1
- 101000944644 Rickettsia typhi (strain ATCC VR-144 / Wilmington) Co-chaperonin GroES Proteins 0.000 claims 1
- 241000344279 bacterium 65 Species 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 229940039696 lactobacillus Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 abstract description 2
- 206010024229 Leprosy Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241001441819 Sphaerium nucleus Species 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 241000344273 bacterium 36 Species 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 101150086609 groEL2 gene Proteins 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
- A61K39/464817—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
결핵 및 나병과 같은 미코박테리아성 감염에 대항한 백신으로 유용한, 코딩 서열을 포유동물 숙주 세포내에서 발현할 수 있는 프로모터에 작용가능하게 결합된 미코박테리아성 스트레스 단백질 또는 프롤린-풍부한 항원 또는 그의 항원으로서 유효한 단편을 코딩하는 코딩 서열로 이루어진 네이키드 핵산 구성체.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 MLhsp65 핵산을 함유하는 레트로비루스로써 감염된 골수 세포 및 정상 골수 세포(1：2비)의 혼합물을 주사한 Balb/c 생쥐의 비장 세포로부터 추출된 DNA의 DNA 서던 블롯 하이브리다이제이션 결과를 나타낸다,
제2도는 MLhsp65 핵산을 함유하는 레트로비루스로써 감염된 골수 세포 및 정상 골수 세포(1：2비)의 혼합물을 주사한 Balb/c 생쥐의 혈액 샘플로부터 추출된 단백질의 웨스턴 블롯 프로빙의 결과를 나타낸다,
제3도는 MLhsp65 유전자를 함유하지 않은 벡터로써 감염된 골수 세포(BMC-Neo), MLhsp65 핵산을 함유하는 레트로비루스로써 감염된 골수 세포(BMC-65) 및 재조합 MLhsp65로써 감염된 골수 세포(rhsp65)를 주사한 생쥐에 대한 지연형 감작능(DTH)의 결과를 나타낸다,
제4도는 제3도에 관련하여 표시된 생쥐군 및 rMLhsp65로써 면역화된 부가적인 군을 결핵균을 독성 균주로써 공격한 결과를 나타낸다,
제5도는 pCDM8ML65 및 pHMGML65의 플라스미드 지도를 나타낸다,
제6도는 근육내 염수(염수), rMLhsp65 및 불완전 프레운트 보조약(hsp65 IFA), pCDM8ML65 및 pHMGML65(65 DNA), 각각 나균 36kD 프롤린 풍부한 항원 유전자(36DNA)를 함유하는 pCDM8 및 pHMG 및 소결핵균 BCG를 주사한 Balb/c 생쥐의 간내의 생존 결핵균의 수를 나타낸다,
제7도는 pCDM8 및 pHMG(대조표준 플라스미드 DNA), 소결핵균 BCG, 나균 36kD 프롤린 풍부한 항원 유전자(36kD 플라스미드 DNA)를 함유하는 pCDM8 및 pHMG 및 pCDM8ML65 및 pHMGML65(65kD 플라스미드 DNA)로써 주사된 과출혈 파케스 알비노 생쥐의 비장(Sp), 간(Li) 및 폐(Lu)내 생존 결핵균의 수를 나타낸다,
제8도는 pCDM8 및 pHMG(대조표준 플라스미드 DNA), 소결핵균 BCG, 나균 36kD 프롤린 풍부한 항원 유진자(36kD 플라스미드 DNA)를 함유하는 pCDM8 및 pHMG 및 pCDM8ML65 및 pHMGML65(65kD 플라스미드 DNA)를 주사한 CBA/Bl0의 비장(Sp), 간(Li) 및 폐(Lu) 내의 생준 결핵균의 수를 나타낸다,
제9도는 pCDM8ML65(65id)로써 피부내로, pCDM8ML65(65im)으로 근육내로, 소결핵군 BCG로 피부내로 또는 pCDM8로 피부내로(대조표준 플라스미드) 주사한 Balb/c 생쥐 또는 미처리된 Balb/c(천연)의 비장(Sp), 간(Li), 및 폐(Lu)내 생존 결핵균의 수를 나타낸다.
Claims (15)
- 미코박테리아성 감염에 대항하는 백신으로서 사용하기 위한 약제의 제조시에, 포유 동물 숙주 세포내에서 코딩 서열을 발현할 수 있는 프로모터에 작용가능하게 결합된 미코박테리아성 스트레스 단백질 또는 프롤린-풍부한 항원 또는 그의 항원으로서 유효한 단편을 코딩하는 코딩 서열로 이루어진 네이키드 핵산 구성체의 용도.
- 제1항에 있어서, 네이키드 핵산 구성체의 코딩 서열이 미코박테리아성 열-쇼크 단백질을 코딩하는 용도.
- 제2항에 있어서, 네이키드 핵산 구성체의 코딩서열이 결핵균, 나균 또는 소결핵균의 70kDa, 65kDa 또는 10kDa 열 쇼크 단백질 또는 그의 항원으로서 유효한 단편을 코딩하는 용도.
- 제3항에 있어서, 네이키드 핵산 구성체의 코딩서열이 나균 65kDa 단백질을 코딩하는 용도.
- 제1항에 있어서, 네이키드 핵산 구성체의 코딩 서열이 결핵균, 나균 또는 소결핵균의 프롤린-풍부한 항원을 코딩하는 용도.
- 제5항에 있어서, 네이키드 핵산 구성체의 코딩 서열이 나균의 36kDa 프롤린-풍부한 항원을 코딩하는 용도.
- 제1항 내지 6항 중 어느 한 항에 있어서, 네이키드 핵산 구성체가 DNA 구성체인 용도.
- 제1항 내지 7항 중 어느 한 항에 있어서, 네이키드 핵산 구성체가 플라스미드인 용도.
- 제1항 내지 6항 중 어느 한 항에 있어서, 네이키드 핵산 구성체가 RNA 구성체인 용도.
- 미코박테리아성 감염에 대항한 백신으로서 사용하기 위한, 제1 내지 9항 중 어느 한 항에 정의된 바의 네이키드 핵산 구성체.
- 제1항 내지 9항 중 어느 한 항에 정의된 바의 네이키드 핵산 구성체 및 허용가능한 캐리어 또는 희석제로 이루어진 백신 조성물.
- 제1항 내지 8항 중 어느 한 항에 정의된 바의 네이키드 핵산 구성체 유효량을 숙주에게 투여하는 것으로 이루어진, 미코박테리아성 감염에 대항한 포유동물 숙주의 면역 처치 방법.
- 코딩 서열을 골수 세포내에서 발현할 수 있는 프로모터에 작용가능하게 결합된 미코박테리아성 스트레스 단백질 또는 프롤린-풍부한 항원 또는 그의 항원으로서 유용한 단편을 코딩하는 코디 서열로 이루어진 네이키드 핵산 구성체로써 트랜스펙트된 골수 세포.
- 제13항에 정의된 바의 골수 세포의 유효량을 숙주에게 투여하는 것으로 이루어진, 미코박테리아성 감염에 대항한 포유동물 숙주이 면역처치 방법.
- 코딩 서열이 미코박테리아성 프롤린-풍부한 항원 또는 그의 항원으로 유효한 단편을 코딩하는, 제1항, 또는 제5항 내지 9항 중 어느 한 항에 정의된 바의 네이키드 핵산 구성체.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9409985.0 | 1994-05-18 | ||
| GB9409985A GB9409985D0 (en) | 1994-05-18 | 1994-05-18 | Vaccine against mycobacterial infections |
| PCT/GB1995/001119 WO1995031216A1 (en) | 1994-05-18 | 1995-05-18 | Vaccine against mycobacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR970703165A true KR970703165A (ko) | 1997-07-03 |
Family
ID=10755365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960706527A KR970703165A (ko) | 1994-05-18 | 1995-05-18 | 미코박테리아성 감염에 대한 백신(vaccine against mycobacterial infections) |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6492145B1 (ko) |
| EP (1) | EP0804230B1 (ko) |
| JP (2) | JP4435870B2 (ko) |
| KR (1) | KR970703165A (ko) |
| AT (1) | ATE189961T1 (ko) |
| AU (1) | AU702162B2 (ko) |
| CA (1) | CA2190515C (ko) |
| DE (1) | DE69515340T2 (ko) |
| ES (1) | ES2146314T3 (ko) |
| GB (1) | GB9409985D0 (ko) |
| WO (1) | WO1995031216A1 (ko) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| US6338852B1 (en) | 1995-09-01 | 2002-01-15 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| US6592877B1 (en) | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| US6290969B1 (en) * | 1995-09-01 | 2001-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| GB9706078D0 (en) * | 1997-03-24 | 1997-05-14 | Chiron Spa | Screening method and proteins and dna identified thereby |
| US6465633B1 (en) | 1998-12-24 | 2002-10-15 | Corixa Corporation | Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis |
| US20070274946A1 (en) * | 1999-04-15 | 2007-11-29 | Norwood Immunoloty, Ltd. | Tolerance to Graft Prior to Thymic Reactivation |
| US20050020524A1 (en) * | 1999-04-15 | 2005-01-27 | Monash University | Hematopoietic stem cell gene therapy |
| US20040258672A1 (en) * | 1999-04-15 | 2004-12-23 | Monash University | Graft acceptance through manipulation of thymic regeneration |
| US20040259803A1 (en) * | 1999-04-15 | 2004-12-23 | Monash University | Disease prevention by reactivation of the thymus |
| US20040265285A1 (en) * | 1999-04-15 | 2004-12-30 | Monash University | Normalization of defective T cell responsiveness through manipulation of thymic regeneration |
| US20040241842A1 (en) * | 1999-04-15 | 2004-12-02 | Monash University | Stimulation of thymus for vaccination development |
| AUPR074500A0 (en) * | 2000-10-13 | 2000-11-09 | Monash University | Treatment of t cell disorders |
| US20060088512A1 (en) * | 2001-10-15 | 2006-04-27 | Monash University | Treatment of T cell disorders |
| KR100992646B1 (ko) * | 2003-07-09 | 2010-11-05 | 제이에스알 가부시끼가이샤 | 파장판 |
| US20080279812A1 (en) * | 2003-12-05 | 2008-11-13 | Norwood Immunology, Ltd. | Disease Prevention and Vaccination Prior to Thymic Reactivation |
| US20070098735A1 (en) * | 2005-10-29 | 2007-05-03 | Chandawarkar Rajiv Y | Methods for the Elimination of Pathogens and Other Particulate Agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68924162T2 (de) * | 1988-06-15 | 1996-04-25 | Whitehead Biomedical Inst | Stressproteine und verwendungen dafür. |
| JP3250802B2 (ja) | 1989-03-21 | 2002-01-28 | バイカル・インコーポレイテッド | 脊椎動物における外因性ポリヌクレオチド配列の発現 |
| JP5163646B2 (ja) * | 2007-07-19 | 2013-03-13 | パナソニック株式会社 | 画像表示装置 |
-
1994
- 1994-05-18 GB GB9409985A patent/GB9409985D0/en active Pending
-
1995
- 1995-05-18 DE DE69515340T patent/DE69515340T2/de not_active Expired - Fee Related
- 1995-05-18 JP JP52947295A patent/JP4435870B2/ja not_active Expired - Fee Related
- 1995-05-18 AU AU25290/95A patent/AU702162B2/en not_active Ceased
- 1995-05-18 CA CA002190515A patent/CA2190515C/en not_active Expired - Fee Related
- 1995-05-18 WO PCT/GB1995/001119 patent/WO1995031216A1/en active IP Right Grant
- 1995-05-18 AT AT95919492T patent/ATE189961T1/de not_active IP Right Cessation
- 1995-05-18 KR KR1019960706527A patent/KR970703165A/ko not_active Application Discontinuation
- 1995-05-18 ES ES95919492T patent/ES2146314T3/es not_active Expired - Lifetime
- 1995-05-18 EP EP95919492A patent/EP0804230B1/en not_active Expired - Lifetime
- 1995-05-18 US US08/737,487 patent/US6492145B1/en not_active Expired - Fee Related
-
2002
- 2002-08-23 US US10/226,935 patent/US20020198168A1/en not_active Abandoned
-
2007
- 2007-07-23 JP JP2007190620A patent/JP2007332149A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0804230A1 (en) | 1997-11-05 |
| JP2007332149A (ja) | 2007-12-27 |
| JP4435870B2 (ja) | 2010-03-24 |
| ES2146314T3 (es) | 2000-08-01 |
| US6492145B1 (en) | 2002-12-10 |
| JPH10500128A (ja) | 1998-01-06 |
| AU2529095A (en) | 1995-12-05 |
| DE69515340D1 (de) | 2000-04-06 |
| DE69515340T2 (de) | 2000-10-19 |
| US20020198168A1 (en) | 2002-12-26 |
| WO1995031216A1 (en) | 1995-11-23 |
| EP0804230B1 (en) | 2000-03-01 |
| AU702162B2 (en) | 1999-02-18 |
| GB9409985D0 (en) | 1994-07-06 |
| ATE189961T1 (de) | 2000-03-15 |
| CA2190515A1 (en) | 1995-11-23 |
| CA2190515C (en) | 2007-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR970703165A (ko) | 미코박테리아성 감염에 대한 백신(vaccine against mycobacterial infections) | |
| CA2131729A1 (en) | Helicobacter pylori proteins useful for vaccines and diagnostics | |
| KR970707281A (ko) | 풀리뉴클레오티드 결핵 백신(A polynucleotide tuberculosis vaccine) | |
| US5571718A (en) | Cloning and expression of soluble truncated variants of Borrelia OspA, OspB and Vmp7 | |
| ATE181572T1 (de) | Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe | |
| MY119003A (en) | Bacterial antigens and vaccine compositions | |
| ITFI920052A1 (it) | Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico. | |
| EP1586646A3 (en) | Lawsonia intracellularis vaccine | |
| US20020172976A1 (en) | P. gingivalis polynucleotides and uses thereof | |
| KR910000177A (ko) | 가금 마이코플라즈마 항원 및 그 유전자를 함유한 재조합벡타, 및 그를 이용한 진단제 및 백신 | |
| Mostaan et al. | Pasteurella multocida PlpE protein polytope as a potential subunit vaccine candidate | |
| DE69101646D1 (de) | Vakzine gegen Coccidiose. | |
| CA2195090A1 (en) | Lkp pilin structural genes and operon of nontypable haemophilus influenzae | |
| EP0862615B1 (en) | Immunity against pasteurella haemolytica leukotoxin | |
| AU2801192A (en) | Preparation of recombinant borrelia proteins | |
| Crocquet-Valdes et al. | Sequence analysis of the 190-kDa antigen-encoding gene of Rickettsia conorii (Malish 7 strain) | |
| ES2377569T3 (es) | Polinucleótidos de Haemophilus parasuis y su uso | |
| Lo et al. | The isolation of recombinant plasmids expressing secreted antigens of Pasteurella haemolytica A1 and the characterization of an immunogenic 60 kDa antigen | |
| EP1518558B1 (en) | Vaccine against infection with Actinobacillus pleuropneumoniae comprising purified ApxIV toxin | |
| Ward et al. | Delivery of non-toxic fragments of Clostridium difficile toxin A to the mucosal immune system | |
| WO1992003553A1 (en) | Footrot vaccine | |
| AU717773B2 (en) | Immunity against pasteurella haemolytica leukotoxin | |
| WO2023088988A1 (en) | A method to produce a vaccine against streptococcus suis and the said vaccine | |
| AU2009230776B2 (en) | Neisseria meningitidis antigens and compositions | |
| EP1305436A2 (en) | Co-expression of recombinant proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |